Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Complicated Skin And Skin Structure Infections (cSSSI) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) 7
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Products under Development by Companies 12
Companies Involved in Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Development 13
Takeda Pharmaceutical Company Limited 13
Rib-X Pharmaceuticals, Inc. 14
Paratek Pharmaceuticals, Inc. 15
Basilea Pharmaceutica Ltd. 16
CrystalGenomics, Inc. 17
Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ceftaroline fosamil - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
omadacycline tosylate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
delafloxacin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CG-400549 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
JNJ-Q2 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ceftobiprole medocaril - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Drug Profile Updates 37
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Dormant Products 43
Complicated Skin And Skin Structure Infections (cSSSI) - Product Development Milestones 44
Featured News & Press Releases 44
Aug 28, 2012: European Commission Approves Zinforo To Treat Skin Infections Or Community Acquired Pneumonia 44
Jun 22, 2012: CHPM Adopts Positive Opinion For Zinforo For Treatment Of Complicated Skin And Soft Tissue Infections 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer

List of Tables
Number of Products Under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2012 7
Products under Development for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Takeda Pharmaceutical Company Limited, H2 2012 13
Rib-X Pharmaceuticals, Inc., H2 2012 14
Paratek Pharmaceuticals, Inc., H2 2012 15
Basilea Pharmaceutica Ltd., H2 2012 16
CrystalGenomics, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Drug Profile Updates 37
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2012 7
Products under Development for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012

Click here to open the POPUP